Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open Label, Single Group Assignment Design Study to Correlate Soluble ST2 With Clinical, Endoscopic and Histological Activity in Moderate to Severe Ulcerative Colitis Patients Under Golimumab.

Next Previous
Trial Profile

An Open Label, Single Group Assignment Design Study to Correlate Soluble ST2 With Clinical, Endoscopic and Histological Activity in Moderate to Severe Ulcerative Colitis Patients Under Golimumab.

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 13 May 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Golimumab (Primary) ; Glucocorticoids; Immunosuppressants
  • Indications Ulcerative colitis
  • Focus Biomarker; Diagnostic use
  • Acronyms EVOLUTION
  • Sponsors Merck Sharp & Dohme

    • Most Recent Events

    • 24 Oct 2018 Primary endpoint has not been met. (Correlation of Serum Soluble ST2 Levels With Histological Activity (Assessed by Geboes Index) at Week 6) according to results presented at the 26th United European Gastroenterology Week.
    • 24 Oct 2018 Primary endpoint has been met. (Correlation of Serum Soluble Human Suppression of Tumorigenicity 2 (ST2) Levels With Endoscopic Activity of Disease (Assessed by Endoscopy Subscore of Mayo Score) at Week 6) according to results presented at the 26th United European Gastroenterology Week.
    • 24 Oct 2018 Results assessing non-invasive serum biomarkers to assess intestinal inflammation and predict clinical response, presented at the 26th United European Gastroenterology Week.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top